AKT1 and metabolic disease: Based on previous research, our work focuses on the positive effect of SHTXF on IR by modulating the InR/PI3K/Akt signaling pathway, not only indicating potential drug targets but also providing key insights for the clinical treatment of T2DM and related metabolic diseases.